High-Grade Astrocytomas - 05/06/18
Doi : 10.1016/S0733-8619(18)30023-9
Patrick Y. Wen, MD a, ⁎, Howard A. Fine, MD b, Peter McL. Black, MD, PhD c, Dennis C. Shrieve, MD, PhD e, Eben Alexander, MD d, e, Jay S. Loeffler, MD e
a From The Brain Tumor Center of Brigham and Women's Hospital, The Dana Färber Cancer Institute, Children's Hospital, and Joint Center for Radiation Therapy; and the Departments of Neurology (PYW), Harvard Medical School, Boston, Massachusetts
b Medicine (HAF), Harvard Medical School, Boston, Massachusetts
c Neurosurgery (PMB), Harvard Medical School, Boston, Massachusetts
d Surgery (EA)
e Radiation Oncology (DCS, EA, JSL), Harvard Medical School, Boston, Massachusetts
*Address reprint requests to: Patrick Y. Wen, MD, Section of Neuro-Oncology, Division of Neurology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115Section of Neuro-OncologyDivision of NeurologyBrigham and Women's Hospital75 Francis StreetBostonMA02115
Résumé |
High-grade astrocytomas are the most common primary brain tumors in adults. Until recently, there has been little progress in the treatment of these tumors. Promising new therapies, however, are emerging based on technologic advances in surgery and radiotherapy; improved understanding of the molecular, cellular, and immunobiologic aspects of these tumors; and advances in gene therapy. This article reviews some of the advances that have been made in the diagnosis and treatment of high-grade astrocytomas.
Le texte complet de cet article est disponible en PDF.© 1995
Elsevier Inc. Tous droits réservés.
Vol 13 - N° 4
P. 875-900 - novembre 1995 Retour au numéro
Article précédent
- Oligodendrogliomas
- Kendra Peterson, J. Gregory Cairncross
- Primary Central Nervous System Lymphoma
- Ronnie J. Freilich, Lisa M. DeAngelis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?